Context Dopamine agonist (DA)-induced impulse control disorder (ICD) in prolactinomas is not sufficiently known. Objective To evaluate the prevalence of DA-induced ICDs and possible risk factors related to these disorders in patients with prolactinoma. Design, Setting and Participants This is a cross-sectional multicenter study involving 308 prolactinoma patients followed-up in tertiary referral centers who received at least 3 months of DA therapy. DA-induced ICDs (pathological gambling, hypersexuality, compulsive shopping and compulsive eating) and impulsivity were assessed using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP) and the Barratt Impulsiveness Scale-11 (BIS-11), respectively. Patients were evaluated in terms of parameters related with ICD development. Results Any ICD prevalence was 17% (n=51). Most common type was hypersexuality (6.5%). While any ICD and hypersexuality were more common in male patients (p=0.009, p<0.001, respectively), compulsive eating was more common in female patients (p=0.046). Current smoking, alcohol use and gambling history were more frequent (p=0.033, p=0.002, p=0.008, respectively) in patients with any ICD. In BIS-11 total, attentional, motor and non-planning scores were significantly higher in patients with any ICD (p<0.001). Current smoking and alcohol use were more frequent (p=0.007, p=0.003, respectively) and percentage increase of testosterone levels at last visit was higher (p=0.021) in male prolactinomas with hypersexuality. Conclusion Any ICD may be seen in one out of six with prolactinoma patients who are receiving DA therapy and endocrinology specialists should be aware of this significant side effect particularly in male patients with a history of gambling, smoking or alcohol use.

Introduction: There are still not enough data showing whether patients with idiopathic hirsutism (IH) also have insulin resistance. The association between polycystic ovary syndrome (PCOS) and insulin resistance is well documented in the literature, but the Rotterdam Consensus has concluded...

Our objective in this study was to evaluate the factors predicting female sexual dysfunction (FSD) in patients with diabetes mellitus (DM). The study included 149 women with DM. Sexual function was evaluated with the Female Sexual Function Index (FSFI) questionnaire, in which total scores under 26.55 characterized the occurrence of FSD (Group 1 > 26.55, Group 2 < 26.55). We recorded the patients' demographic, metabolic, and hormonal data. Ophthalmologic, neurologic, and renal complications were also evaluated. The antioxidant status of the patients in both groups was determined by measuring the activity of the enzymes paraoxonase-1 (PON-1) and arylesterase (ARE). Based on the FSFI scores, 60 patients were allocated to Group 1 (26.6 ± 12.3) and 89 to Group 2 (22.6 ± 9.5). Group 2 compared with Group 1 had significantly (p < 0.05) higher mean concentrations of glycated hemoglobin (HbA1c), glucose, triglycerides, and insulin, along with higher rates of metformin use, smoking, retinopathy, and nephropathy. The mean serum ARE concentrations were significantly lower in Group 2 compared with Group 1 (p = 0.000), but the mean serum PON-1 concentrations were similar between both groups (p = 0.218). On multivariable regression analysis, age, ARE activity, Beck Depression Inventory (BDI) score, and menopause were significant independent predictors of FSD (p < 0.05). In this study, we evaluated the predictive factors determining FSD caused by DM. Despite the significant results found in our study, future randomized controlled studies with a long follow-up and a larger number of patients are required to determine how DM affects FSD.